Erythropoietin (EPO) is primarily indicated for patients suffering with Chronic Renal Failure (CRF), a condition where patients suffer from anemia due impaired production of EPO and the resulting deficiency of EPO. Amgen Inc. (USA) was the first to launch EPO under the brand name Epogen® in 1989 as injection for intravenous or subcutaneous use.
Gennova launched a biosimilar recombinant EPO, made in CHO cells, under the brand name Vintor® for intravenous or subcutaneous administration in 2007. Vintor is presented in different formulations as Vintor® -2000, -3000, -4000, -6000, -10000 and 20000 IU containing EPO concentrated solution Ph. Eur. 2000, 3000, 4000, 6000, 10000 and 20000 IU, respectively. Vintor® is the market leader in India today (as per IMS) despite several competing brands being available in the country.
One of the earliest brands commercially available (Since 2007)
Periodic safety reports of more than 34 ,00,000 patients submitted to the DCG(I).
One of the leading biosimilar products in Indian market.
Vintor® product
Prescribed for Renal care and Oncology
Isoforms matching with reference standard
CD spectra of Gennova’s EPO is similar to reference standard
CZE profile of Gennova’s EPO is similar to reference standard
Batch release on the basis of biological activity assessment using normocythaemic mice [B6D2F1, cross between C57BL/6J (B6) female x DBA/2J (D2) male]
Related protein impurity of Gennova’s EPO is similar to reference standard
Smarter ways to ensure the effectiveness of EPO
- Use superior quality of Iron
- Maintain Hepcidin in normal range
